<DOC>
	<DOCNO>NCT01966614</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy single treatment PRX302 treatment Benign Prostatic Hyperplasia ( BPH ) compare placebo .</brief_summary>
	<brief_title>Randomized , Double-Blind , Vehicle-Controlled , Multicenter Safety Efficacy Study Intraprostatic PRX302 LUTS BPH</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Age ≥50 year Lower Urinary Tract Symptoms ( LUTS ) attributable BPH ≥6 month IPSS ≥15 Maximum urine flow ( Qmax ) 5 15 mL/sec Prostate volume 30 100 mL determine TRUS Serum prostatespecific antigen ( PSA ) value &lt; 10 ng/mL Postvoid residual ( PVR ) &lt; = 200 mL Inability void ≥125 mL urine Prior surgery/MIST BPH Presence history certain condition could interfere study result endanger subject Use certain prescribed medication could interfere study result</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Benign prostatic hyperplasia</keyword>
	<keyword>BPH</keyword>
	<keyword>Enlarged prostate</keyword>
	<keyword>Lower urinary tract symptom ( LUTS )</keyword>
</DOC>